Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Ecancermedicalscience|May 30, 2013
International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspectiveEmad Shash, Anastassia Negrouk, Sandrine Marreaud, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trialsJulien Péron, Anouk Neven, Laurence Collette, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2009
EORTC-GU group expert opinion on metastatic renal cell cancerTheo M de Reijke, Joaquim Bellmunt, Hein van Poppel, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding studyXavier Paoletti, Benoît Baron, Patrick Schöffski, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2008
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignanciesVéronique Diéras, Jacques Bonneterre, Valérie Laurence, et al.
Oncology|October 16, 2015
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061Linda Cerbone, Cora N Sternberg, Lisa Sengeløv, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986Maria De Santis, Joaquim Bellmunt, Graham Mead, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2024
The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trialsArmelle Dufresne, Lars H Lindner, Jana Striefler, et al.
Breast (Edinburgh, Scotland)|November 3, 2007
Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trialBojana Pajk, Tanja Cufer, Peter Canney, et al.
Pageof 7